ClinicalTrials.gov
skipnavHome|Search|Browse|Resources|Help|What's New|About

AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Aromatase Inhibitor Therapy for Non-metastatic Breast Cancer

This study is currently recruiting patients.

Sponsored by: Amgen
Information provided by: Amgen

Purpose

The purpose of this trial is to evaluate AMG 162 in the treatment of bone loss in subjects undergoing Aromatase Inhibitor Therapy for Non-metastatic Breast Cancer.

Condition Treatment or Intervention Phase
Breast Cancer
  Drug: AMG 162
 Phase III

MedlinePlus related topics:  Breast Cancer
Genetics Home Reference related topics:  breast cancer

Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Placebo Control

Official Title: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Aromatase Inhibitor Therapy for Non-metastatic Breast Cancer

Eligibility

Ages Eligible for Study:  18 Years and above,  Genders Eligible for Study:  Female

Criteria

Other criteria also apply.

Location and Contact Information

For additional information regarding investigative sites for this trial, contact the Amgen Call Center at:      866-572-6436 

California
      Research Site, Torrance,  California,  United States; Recruiting

Connecticut
      Research Site, Stamford,  Connecticut,  United States; Recruiting

District of Columbia
      Research Site, Washington,  District of Columbia,  United States; Recruiting

Florida
      Research Site, Gainesville,  Florida,  United States; Recruiting

      Research Site, Ormond Beach,  Florida,  United States; Recruiting

      Research Site, Plantation,  Florida,  United States; Recruiting

Missouri
      Research Site, St. Louis,  Missouri,  United States; Recruiting

New Jersey
      Research Site, Livingston,  New Jersey,  United States; Recruiting

New York
      Research Site, Rochester,  New York,  United States; Recruiting

Ohio
      Research Site, Cleveland,  Ohio,  United States; Recruiting

South Carolina
      Research Site, Columbia,  South Carolina,  United States; Recruiting

      Research Site, Charleston,  South Carolina,  United States; Recruiting

Tennessee
      Research Site, Germantown,  Tennessee,  United States; Recruiting

      Research Site, Memphis,  Tennessee,  United States; Recruiting

Virginia
      Research Site, Abingdon,  Virginia,  United States; Recruiting

Washington
      Research Site, Tacoma,  Washington,  United States; Recruiting

      Research Site, Seattle,  Washington,  United States; Recruiting

More Information

AmgenTrials clinical trials website

CenterWatch Clinical Trials Listing Service

Study ID Numbers:  20040135
Record last reviewed:  October 2004
Record first received:  August 9, 2004
ClinicalTrials.gov Identifier:  NCT00089661
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2004-11-10
line
U.S. National Library of Medicine, Contact NLM Customer Service
National Institutes of Health, Department of Health & Human Services
Copyright, Privacy, Accessibility, Freedom of Information Act